Qiming Leads $20M Round In Chinese Start-Up Connect Biopharmaceuticals

Login to View

Qiming Venture Capital has led a US$20 million series A round in Connect Biopharmaceuticals Ltd., a clinical-stage company developing immune modulators for autoimmune diseases and cancer treatment.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in